Sign inJoin waitlistJoin the waitlist

Basak Dogan

Director, Breast Imaging Research, Director, Clinical Breast MRI · University of Texas Southwestern Medical Center

Credentials: · · ·

History

Breast Imaging Research · University of Texas Southwestern Medical Center
Present
University of Texas Southwestern Medical Center
Present
University of Texas Southwestern Medical Center
Present

Ankara University School of Medicine
1997–2001
Hacettepe University Faculty of Medicine
1993–1997
Academic Medical Center Hospital
1996

Research

Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted…
Journal of Clinical Oncology · 2016 · 733 citations
BI-RADS® fifth edition: A summary of changes
Review · Diagnostic and Interventional Imaging · 2017 · Last of 5 authors · 369 citations
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial
Radiology · 2018 · 224 citations

Wei Yang
23 papers · 6 as a resident
Gary Whitman
21 papers
Berat Ozcan
15 papers · 7 as a resident
MD
Mark Dryden
11 papers
Ann Mootz
10 papers
Jessica Porembka
10 papers
Katerina Dodelzon
10 papers
Stephen Seiler
8 papers
Beatriz Adrada
7 papers · 1 as a fellow
Bonnie Joe
7 papers
KO
Karen Oh
7 papers
Rosalind Candelaria
7 papers

Clinical trials

OA for Breast Cancer NAC Response
Principal investigator · Completed
Seno Medical Instruments Inc.
2021–2023
Performance of Contrast-Enhanced Spectral Mammography to Assess Neoadjuvant Chemotherapy Response (CEDM)
Principal investigator · Terminated · Phase 4
University of Texas Southwestern Medical Center
2020–2022
Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients
Principal investigator · Completed
M.D. Anderson Cancer Center
2015–2016
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
Site PI · Recruiting
ARTIDIS AG
2023–2035